50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
One Stock Doubles Your Money, During Crisis? (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
One Stock Doubles Your Money, During Crisis? (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
One Stock Doubles Your Money, During Crisis? (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
One Stock Doubles Your Money, During Crisis? (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
One Stock Doubles Your Money, During Crisis? (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
One Stock Doubles Your Money, During Crisis? (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West
S&P 500   3,647.29
DOW   29,134.99
QQQ   274.48
Layoffs Aren't the Solution to Your Profitability Crisis. Here's the Simple 4-Step Process You Should Be Following Instead.
One Stock Doubles Your Money, During Crisis? (Ad)
Is There Value In These Growth Stocks?
Build A Better Tech Portfolio With Jabil Inc.
One Stock Doubles Your Money, During Crisis? (Ad)
US stocks end mixed a day after Dow entered a bear market
Autodesk Is A Mature Company Still Acting Like A Growth Stock
One Stock Doubles Your Money, During Crisis? (Ad)
Leaks on Russian gas pipelines raise concerns about sabotage
Vote in Ukraine's Russia-held areas stokes tension with West

Supernus Pharmaceuticals - SUPN Stock Forecast, Price & News

$31.80
-0.74 (-2.27%)
(As of 09/27/2022 12:00 AM ET)
Add
Compare
Today's Range
$31.44
$33.15
50-Day Range
$29.51
$35.51
52-Week Range
$24.95
$36.08
Volume
701,346 shs
Average Volume
377,235 shs
Market Capitalization
$1.70 billion
P/E Ratio
31.49
Dividend Yield
N/A
Price Target
$41.00

Supernus Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
28.9% Upside
$41.00 Price Target
Short Interest
Bearish
11.97% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.35
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
Selling Shares
$2.16 M Sold Last Quarter
Proj. Earnings Growth
-31.79%
From $1.51 to $1.03 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.96 out of 5 stars

Medical Sector

708th out of 1,071 stocks

Pharmaceutical Preparations Industry

332nd out of 531 stocks

SUPN stock logo

About Supernus Pharmaceuticals (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset epilepsy seizures in adults and children between 6 to 17 years of age. The company's commercial products also comprise Qelbree, a selective norepinephrine reuptake inhibitor indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in pediatric patients 6 to 17 years of age; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, its product candidates include Qelbree (SPN-812), which has completed Phase III clinical trials that is used for the treatment of ADHD; SPN-830, a late-stage drug/device combination product candidate for the prevention of off episodes in PD patients; SPN-817, a novel product candidate in Phase I clinical trials for the treatment of severe epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; and SPN-443 and SPN-446, which are in preclinical stage for treating CNS. The company markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. The company was incorporated in 2005 and is headquartered in Rockville, Maryland.

Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Stock News Headlines

Best Momentum Stocks to Buy for August 8th
Supernus: A Work In Progress
See More Headlines
Receive SUPN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Supernus Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SUPN Company Calendar

Last Earnings
8/04/2022
Today
9/27/2022
Next Earnings (Estimated)
11/02/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:SUPN
CUSIP
86845910
Employees
575
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$41.00
High Stock Price Forecast
$44.00
Low Stock Price Forecast
$38.00
Forecasted Upside/Downside
+28.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$53.42 million
Pretax Margin
9.06%

Debt

Sales & Book Value

Annual Sales
$579.78 million
Cash Flow
$1.92 per share
Book Value
$15.43 per share

Miscellaneous

Free Float
48,841,000
Market Cap
$1.70 billion
Optionable
Optionable
Beta
1.01

Key Executives

  • Mr. Jack A. Khattar (Age 61)
    Founder, Pres, CEO, Sec. & Director
    Comp: $1.78M
  • Mr. Timothy C. Dec (Age 63)
    Sr. VP & CFO
    Comp: $457.62k
  • Dr. Padmanabh P. Bhatt (Age 65)
    Chief Scientific Officer & Sr. VP of Intellectual Property
    Comp: $598.61k
  • Ms. Tami T. Martin (Age 67)
    Sr. VP of Regulatory Affairs
    Comp: $508.5k
  • Dr. Jonathan Rubin (Age 61)
    Sr. VP of R&D and Chief Medical Officer
    Comp: $557.7k
  • Mr. Kevin T. Anderson (Age 60)
    Compliance Officer
  • Dr. Todd Horich M.B.A.
    Ph.D., Sr. VP of Marketing & Market Access
  • Mr. Taylor Raiford
    Sr. VP of Sales
  • Dr. Bryan A. Roecklein Ph.D.
    Sr. VP of Corp. Devel.
  • Mr. Frank Mottola (Age 50)
    Sr. VP of Quality, GMP Operations & Information Technology













SUPN Stock - Frequently Asked Questions

Should I buy or sell Supernus Pharmaceuticals stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SUPN shares.
View SUPN analyst ratings
or view top-rated stocks.

What is Supernus Pharmaceuticals' stock price forecast for 2022?

2 brokers have issued 12 month target prices for Supernus Pharmaceuticals' shares. Their SUPN share price forecasts range from $38.00 to $44.00. On average, they predict the company's share price to reach $41.00 in the next twelve months. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for SUPN
or view top-rated stocks among Wall Street analysts.

How have SUPN shares performed in 2022?

Supernus Pharmaceuticals' stock was trading at $29.16 at the beginning of the year. Since then, SUPN stock has increased by 9.1% and is now trading at $31.80.
View the best growth stocks for 2022 here
.

When is Supernus Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 2nd 2022.
View our SUPN earnings forecast
.

How were Supernus Pharmaceuticals' earnings last quarter?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) issued its quarterly earnings data on Thursday, August, 4th. The specialty pharmaceutical company reported $0.14 earnings per share for the quarter, missing analysts' consensus estimates of $0.29 by $0.15. The specialty pharmaceutical company had revenue of $170.10 million for the quarter, compared to the consensus estimate of $164.23 million. Supernus Pharmaceuticals had a net margin of 9.12% and a trailing twelve-month return on equity of 6.98%. The company's quarterly revenue was up 20.4% compared to the same quarter last year. During the same quarter in the prior year, the business earned $0.43 earnings per share.

What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?

Supernus Pharmaceuticals issued an update on its FY 2022 earnings guidance on Thursday, August, 25th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $640.00 million-$680.00 million, compared to the consensus revenue estimate of $673.56 million.

What is Jack A. Khattar's approval rating as Supernus Pharmaceuticals' CEO?

20 employees have rated Supernus Pharmaceuticals Chief Executive Officer Jack A. Khattar on Glassdoor.com. Jack A. Khattar has an approval rating of 81% among the company's employees.

What other stocks do shareholders of Supernus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Supernus Pharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), Gilead Sciences (GILD), Alibaba Group (BABA), Exelixis (EXEL), Pfizer (PFE), GW Pharmaceuticals (GWPH), Netflix (NFLX), Corcept Therapeutics (CORT) and Cara Therapeutics (CARA).

What is Supernus Pharmaceuticals' stock symbol?

Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."

Who are Supernus Pharmaceuticals' major shareholders?

Supernus Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Polaris Capital Management LLC (5.46%), Macquarie Group Ltd. (4.37%), Stephens Investment Management Group LLC (3.02%), Loomis Sayles & Co. L P (3.02%), Renaissance Technologies LLC (2.62%) and Aristotle Capital Boston LLC (2.37%). Insiders that own company stock include Frederick M Hudson, Gregory S Patrick, Jack A Khattar, Stefan KF Schwabe and Tami Tillotson Martin.
View institutional ownership trends
.

How do I buy shares of Supernus Pharmaceuticals?

Shares of SUPN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Supernus Pharmaceuticals' stock price today?

One share of SUPN stock can currently be purchased for approximately $31.80.

How much money does Supernus Pharmaceuticals make?

Supernus Pharmaceuticals (NASDAQ:SUPN) has a market capitalization of $1.70 billion and generates $579.78 million in revenue each year. The specialty pharmaceutical company earns $53.42 million in net income (profit) each year or $1.01 on an earnings per share basis.

How many employees does Supernus Pharmaceuticals have?

The company employs 575 workers across the globe.

How can I contact Supernus Pharmaceuticals?

Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The official website for the company is www.supernus.com. The specialty pharmaceutical company can be reached via phone at (301) 838-2500, via email at gpatrick@supernus.com, or via fax at 301-838-2501.

This page (NASDAQ:SUPN) was last updated on 9/28/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.